Cargando…
H2Bub1 loss is an early contributor to clear cell ovarian cancer progression
Epigenetic aberrations, including posttranslational modifications of core histones, are major contributors to cancer. Here, we define the status of histone H2B monoubiquitylation (H2Bub1) in clear cell ovarian carcinoma (CCOC), low-grade serous carcinoma, and endometrioid carcinomas. We report that...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371241/ https://www.ncbi.nlm.nih.gov/pubmed/37345659 http://dx.doi.org/10.1172/jci.insight.164995 |
_version_ | 1785078107460337664 |
---|---|
author | Ferrari, Adam J. Rawat, Priyanka Rendulich, Hannah S. Annapragada, Akshaya V. Kinose, Yasuto Zhang, Xiaoming Devins, Kyle Budina, Anna Scharpf, Robert B. Mitchell, Marilyn A. Tanyi, Janos L. Morgan, Mark A. Schwartz, Lauren E. Soong, T. Rinda Velculescu, Victor E. Drapkin, Ronny |
author_facet | Ferrari, Adam J. Rawat, Priyanka Rendulich, Hannah S. Annapragada, Akshaya V. Kinose, Yasuto Zhang, Xiaoming Devins, Kyle Budina, Anna Scharpf, Robert B. Mitchell, Marilyn A. Tanyi, Janos L. Morgan, Mark A. Schwartz, Lauren E. Soong, T. Rinda Velculescu, Victor E. Drapkin, Ronny |
author_sort | Ferrari, Adam J. |
collection | PubMed |
description | Epigenetic aberrations, including posttranslational modifications of core histones, are major contributors to cancer. Here, we define the status of histone H2B monoubiquitylation (H2Bub1) in clear cell ovarian carcinoma (CCOC), low-grade serous carcinoma, and endometrioid carcinomas. We report that clear cell carcinomas exhibited profound loss, with nearly all cases showing low or negative H2Bub1 expression. Moreover, we found that H2Bub1 loss occurred in endometriosis and atypical endometriosis, which are established precursors to CCOCs. To examine whether dysregulation of a specific E3 ligase contributes to the loss of H2Bub1, we explored expression of ring finger protein 40 (RNF40), ARID1A, and UBR7 in the same case cohort. Loss of RNF40 was significantly and profoundly correlated with loss of H2Bub1. Using genome-wide DNA methylation profiles of 230 patients with CCOC, we identified hypermethylation of RNF40 in CCOC as a likely mechanism underlying the loss of H2Bub1. Finally, we demonstrated that H2Bub1 depletion promoted cell proliferation and clonogenicity in an endometriosis cell line. Collectively, our results indicate that H2Bub1 plays a tumor-suppressive role in CCOCs and that its loss contributes to disease progression. |
format | Online Article Text |
id | pubmed-10371241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-103712412023-07-27 H2Bub1 loss is an early contributor to clear cell ovarian cancer progression Ferrari, Adam J. Rawat, Priyanka Rendulich, Hannah S. Annapragada, Akshaya V. Kinose, Yasuto Zhang, Xiaoming Devins, Kyle Budina, Anna Scharpf, Robert B. Mitchell, Marilyn A. Tanyi, Janos L. Morgan, Mark A. Schwartz, Lauren E. Soong, T. Rinda Velculescu, Victor E. Drapkin, Ronny JCI Insight Research Article Epigenetic aberrations, including posttranslational modifications of core histones, are major contributors to cancer. Here, we define the status of histone H2B monoubiquitylation (H2Bub1) in clear cell ovarian carcinoma (CCOC), low-grade serous carcinoma, and endometrioid carcinomas. We report that clear cell carcinomas exhibited profound loss, with nearly all cases showing low or negative H2Bub1 expression. Moreover, we found that H2Bub1 loss occurred in endometriosis and atypical endometriosis, which are established precursors to CCOCs. To examine whether dysregulation of a specific E3 ligase contributes to the loss of H2Bub1, we explored expression of ring finger protein 40 (RNF40), ARID1A, and UBR7 in the same case cohort. Loss of RNF40 was significantly and profoundly correlated with loss of H2Bub1. Using genome-wide DNA methylation profiles of 230 patients with CCOC, we identified hypermethylation of RNF40 in CCOC as a likely mechanism underlying the loss of H2Bub1. Finally, we demonstrated that H2Bub1 depletion promoted cell proliferation and clonogenicity in an endometriosis cell line. Collectively, our results indicate that H2Bub1 plays a tumor-suppressive role in CCOCs and that its loss contributes to disease progression. American Society for Clinical Investigation 2023-06-22 /pmc/articles/PMC10371241/ /pubmed/37345659 http://dx.doi.org/10.1172/jci.insight.164995 Text en © 2023 Ferrari et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Ferrari, Adam J. Rawat, Priyanka Rendulich, Hannah S. Annapragada, Akshaya V. Kinose, Yasuto Zhang, Xiaoming Devins, Kyle Budina, Anna Scharpf, Robert B. Mitchell, Marilyn A. Tanyi, Janos L. Morgan, Mark A. Schwartz, Lauren E. Soong, T. Rinda Velculescu, Victor E. Drapkin, Ronny H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title | H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title_full | H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title_fullStr | H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title_full_unstemmed | H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title_short | H2Bub1 loss is an early contributor to clear cell ovarian cancer progression |
title_sort | h2bub1 loss is an early contributor to clear cell ovarian cancer progression |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371241/ https://www.ncbi.nlm.nih.gov/pubmed/37345659 http://dx.doi.org/10.1172/jci.insight.164995 |
work_keys_str_mv | AT ferrariadamj h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT rawatpriyanka h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT rendulichhannahs h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT annapragadaakshayav h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT kinoseyasuto h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT zhangxiaoming h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT devinskyle h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT budinaanna h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT scharpfrobertb h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT mitchellmarilyna h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT tanyijanosl h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT morganmarka h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT schwartzlaurene h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT soongtrinda h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT velculescuvictore h2bub1lossisanearlycontributortoclearcellovariancancerprogression AT drapkinronny h2bub1lossisanearlycontributortoclearcellovariancancerprogression |